Nipro’s products are key to the supply chain of other life sciences companies that produce injectable products, such as those manufactured by Novo Nordisk ... its footprint and offering high-end ...

Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk continues to witness strong growth across its portfolio of diabetes and obesity care medications. The company's tailwinds include expanded indications and new geographic markets.

Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity. The Danish ...

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of Denmark after cashing in on the weight-loss drug boom. The Novo Nordisk ...

Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's ...